Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States

被引:48
作者
Raison, Charles L. [1 ]
Jain, Rakesh [2 ]
Penn, Andrew D. [3 ]
Cole, Steven P. [4 ]
Jain, Saundra [5 ]
机构
[1] Univ Wisconsin Madison, Dept Human Dev, Family Studies, Schoolof Human Ecol, Madison, WI USA
[2] Texas Tech Univ Hlth Sci Ctr Med Sch, Dept Psychiat, Lubbock, TX USA
[3] Univ Calif San Francisco, Sch Nursing, San Francisco, CA USA
[4] Res Design Associates, Res Design Associates, Yorktown Hts, NY USA
[5] Univ Texas Austin, Sch Nursing, Austin, TX USA
关键词
psychedelics; depression; anxiety; well-being; psilocybin; ayahuasca; harms; patterns of use; LIFE-THREATENING CANCER; PSILOCYBIN TREATMENT; DECREASES;
D O I
10.3389/fpsyt.2022.831092
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A cross-sectional, online survey was completed by 2,510 adults reporting at least one lifetime psychedelic experience. Participants retrospectively completed a battery of instruments assessing depression, anxiety, and emotional well-being prior to and following psychedelic exposure. Participants also reported preferred psychedelic agent, number of uses, and harms attributed to psychedelic use. Psychedelic use was associated with significant improvements in depressive and anxious symptoms and with increased emotional well-being. These improvements increased in magnitude with increasing psychedelic exposure, with a ceiling effect. However, improvements were noted following a single lifetime use. Strong evidence for benefit of one preferred psychedelic agent over another was not observed, but enduring increases in factors related to mystical-experience and prosocial perspective taking associated with enhanced mental health. Thirteen percent of the survey sample (n = 330) endorsed at least one harm from psychedelic use, and these participants reported less mental health benefit. Results from the current study add to a growing database indicating that psychedelic use-even outside the context of clinical trials-may provide a wide range of mental health benefits, while also posing some risk for harm in a minority of individuals.
引用
收藏
页数:11
相关论文
共 44 条
[1]   Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer [J].
Agin-Liebes, Gabrielle, I ;
Malone, Tara ;
Yalch, Matthew M. ;
Mennenga, Sarah E. ;
Ponte, K. Linnae ;
Guss, Jeffrey ;
Bossis, Anthony P. ;
Grigsby, Jim ;
Fischer, Stacy ;
Ross, Stephen .
JOURNAL OF PSYCHOPHARMACOLOGY, 2020, 34 (02) :155-166
[2]  
Alexandrov N., 2020, PSYCHEDELICS IND INS
[3]   Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study [J].
Bogenschutz, Michael P. ;
Forcehimes, Alyssa A. ;
Pommy, Jessica A. ;
Wilcox, Claire E. ;
Barbosa, P. C. R. ;
Strassman, Rick J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (03) :289-299
[4]   Pivotal mental states [J].
Brouwer, Ari ;
Carhart-Harris, Robin Lester .
JOURNAL OF PSYCHOPHARMACOLOGY, 2021, 35 (04) :319-352
[5]   Psilocybin with psychological support for treatment-resistant depression: six-month follow-up [J].
Carhart-Harris, R. L. ;
Bolstridge, M. ;
Day, C. M. J. ;
Rucker, J. ;
Watts, R. ;
Erritzoe, D. E. ;
Kaelen, M. ;
Giribaldi, B. ;
Bloomfield, M. ;
Pilling, S. ;
Rickard, J. A. ;
Forbes, B. ;
Feilding, A. ;
Taylor, D. ;
Curran, H. V. ;
Nutt, D. J. .
PSYCHOPHARMACOLOGY, 2018, 235 (02) :399-408
[6]   Trial of Psilocybin versus Escitalopram for Depression [J].
Carhart-Harris, Robin ;
Giribaldi, Bruna ;
Watts, Rosalind ;
Baker-Jones, Michelle ;
Murphy-Beiner, Ashleigh ;
Murphy, Roberta ;
Martell, Jonny ;
Blemings, Allan ;
Erritzoe, David ;
Nutt, David J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1402-1411
[7]   Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? [J].
Carhart-Harris, Robin L. ;
Wagner, Anne C. ;
Agrawal, Manish ;
Kettner, Hannes ;
Rosenbaum, Jerold F. ;
Gazzaley, Adam ;
Nutt, David J. ;
Erritzoe, David .
JOURNAL OF PSYCHOPHARMACOLOGY, 2022, 36 (01) :6-11
[8]   Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study [J].
Carhart-Harris, Robin L. ;
Bolstridge, Mark ;
Rucker, James ;
Day, Camilla M. J. ;
Erritzoe, David ;
Kaelen, Mendel ;
Bloomfield, Michael ;
Rickard, James A. ;
Forbes, Ben ;
Feilding, Amanda ;
Taylor, David ;
Pilling, Steve ;
Curran, Valerie H. ;
Nutt, David J. .
LANCET PSYCHIATRY, 2016, 3 (07) :619-627
[9]   Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial [J].
Davis, Alan K. ;
Barrett, Frederick S. ;
May, Darrick G. ;
Cosimano, Mary P. ;
Sepeda, Nathan D. ;
Johnson, Matthew W. ;
Finan, Patrick H. ;
Griffiths, Roland R. .
JAMA PSYCHIATRY, 2021, 78 (05) :481-489
[10]   Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety [J].
Davis, Alan K. ;
Barrett, Frederick S. ;
Griffiths, Roland R. .
JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE, 2020, 15 :39-45